^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    MEDI7247

    i
    Other names: MEDI7247, MEDI-7247, MEDI 7247
    Company:
    AstraZeneca
    Drug class:
    DNA replication inhibitor, SLC1A5-targeted antibody-drug conjugate
    Related drugs:
    8ms
    ASCT2-Targeting Antibody-Drug Conjugate MEDI7247 in Adult Patients with Relapsed/Refractory Hematological Malignancies: A First-in-Human, Phase 1 Study. (PubMed, Target Oncol)
    Thrombocytopenia and neutropenia limited repeat dosing. Although limited clinical activity was detected, the dose-escalation phase was stopped early without establishing an MTD. The study was registered with ClinicalTrials.gov (NCT03106428).
    P1 data • Journal
    |
    SLC1A5 (Solute Carrier Family 1 Member 5)
    |
    MEDI7247
    over1year
    Preclinical radiolabeling, in vivo biodistribution and positron emission tomography of a novel pyrrolobenzodiazepine (PBD)-based antibody drug conjugate targeting ASCT2. (PubMed, Nucl Med Biol)
    MEDI7247 (human anti-ASCT2 antibody conjugated with pyrrolobenzodiazepine (PBD)) and MEDI7519 (MEDI7247 without PBD drug conjugate) and an isotype control antibody drug conjugate construct were conjugated with p-isothiocyanatobenzyl-deferoxamine (Df) and radiolabeled with zirconium-89. Preclinical biodistribution analyses of [Zr]Zr-Df-MEDI7247 and [Zr]Zr-Df-MEDI7519 showed the biodistribution pattern of anti-ASCT2 ADC MEDI7247 was similar to parental MEDI7519, and both antibodies showed specific tumor uptake compared to an isotype control ADC. This study highlights an important role nuclear medicine imaging techniques can play in early preclinical assessment of drug specificity as part of the drug development pipeline.
    Preclinical • Journal
    |
    SLC1A5 (Solute Carrier Family 1 Member 5)
    |
    MEDI7247